JonesTrading Keeps Their Buy Rating on Chimerix (CMRX)

By Carrie Williams

In a report released today, Soumit Roy from JonesTrading reiterated a Buy rating on Chimerix (CMRXResearch Report), with a price target of $14.00. The company’s shares closed last Friday at $8.45.

According to, Roy is a 5-star analyst with an average return of 54.1% and a 52.7% success rate. Roy covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Monopar Therapeutics Inc, and Adaptimmune Therapeutics.

Currently, the analyst consensus on Chimerix is a Strong Buy with an average price target of $16.25, representing an 89.2% upside. In a report issued on March 31, Wedbush also initiated coverage with a Buy rating on the stock with a $14.00 price target.

See today’s analyst top recommended stocks >>

Based on Chimerix’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $1.12 million and GAAP net loss of $11.68 million. In comparison, last year the company earned revenue of $6.77 million and had a GAAP net loss of $3.5 million.

Based on the recent corporate insider activity of 10 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CMRX in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Chimerix, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes Brincidofovir for the treatment of adenovirus, cytomegalovirus, and smallpox. The company was founded by George R. Painter, III and Timothy Wollaeger in April 2000 and is headquartered in Durham, NC.